PT  - JOURNAL ARTICLE
AU  - Sonabend, Raphael
AU  - Whittles, Lilith K.
AU  - Imai, Natsuko
AU  - Perez-Guzman, Pablo N
AU  - Knock, Edward S
AU  - Rawson, Thomas
AU  - Gaythorpe, Katy AM
AU  - Djaafara, Bimandra A
AU  - Hinsley, Wes
AU  - FitzJohn, Richard G
AU  - Lees, John A
AU  - Kanapram, Divya Thekke
AU  - Volz, Erik M
AU  - Ghani, Azra C
AU  - Ferguson, Neil M
AU  - Baguelin, Marc
AU  - Cori, Anne
TI  - Non-pharmaceutical interventions, vaccination and the Delta variant: epidemiological insights from modelling England’s COVID-19 roadmap out of lockdown
AID  - 10.1101/2021.08.17.21262164
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.17.21262164
4099  - http://medrxiv.org/content/early/2021/08/18/2021.08.17.21262164.short
4100  - http://medrxiv.org/content/early/2021/08/18/2021.08.17.21262164.full
AB  - Background England’s COVID-19 “roadmap out of lockdown” set out the timeline and conditions for the stepwise lifting of non-pharmaceutical interventions (NPIs) as vaccination roll-out continued. Here we assess the roadmap, the impact of the Delta variant, and potential future epidemic trajectories.Methods We extended a model of SARS-CoV-2 transmission to incorporate vaccination and multi-strain dynamics to explicitly capture the emergence of the Delta variant. We calibrated the model to English surveillance data using a Bayesian evidence synthesis framework, then modelled the potential trajectory of the epidemic for a range of different schedules for relaxing NPIs.Findings The roadmap was successful in offsetting the increased transmission resulting from lifting NPIs with increasing population immunity through vaccination. However due to the emergence of Delta, with an estimated transmission advantage of 73% (95%CrI: 68-79) over Alpha, fully lifting NPIs on 21 June 2021 as originally planned may have led to 3,400 (95%CrI: 1,300-4,400) peak daily hospital admissions under our central parameter scenario. Delaying until 19 July reduced peak hospitalisations by three-fold to 1,400 (95%CrI: 700-1,500) per day. There was substantial uncertainty in the epidemic trajectory, with particular sensitivity to estimates of vaccine effectiveness and the intrinsic transmissibility of Delta.Interpretation Our findings show that the risk of a large wave of COVID hospitalisations resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage. However, with Delta, it may not be possible to fully lift NPIs without a third wave of hospitalisations and deaths, even if vaccination coverage is high. Variants of concern, their transmissibility, vaccine uptake, and vaccine effectiveness must be carefully monitored as countries relax pandemic control measures.Funding National Institute for Health Research, UK Medical Research Council, Wellcome Trust, UK Foreign, Commonwealth & Development Office.Evidence before this study We searched PubMed up to 23 July 2021 with no language restrictions using the search terms: (COVID-19 or SARS-CoV-2 or 2019-nCoV or “novel coronavirus”) AND (vaccine or vaccination) AND (“non pharmaceutical interventions” OR “non-pharmaceutical interventions) AND (model*). We found nine studies that analysed the relaxation of controls with vaccination roll-out. However, none explicitly analysed real-world evidence balancing lifting of interventions, vaccination, and emergence of the Delta variant.Added value of this study Our data synthesis approach combines real-world evidence from multiple data sources to retrospectively evaluate how relaxation of COVID-19 measures have been balanced with vaccination roll-out. We explicitly capture the emergence of the Delta variant, its transmissibility over Alpha, and quantify its impact on the roadmap. We show the benefits of maintaining NPIs whilst vaccine coverage continues to increase and capture key uncertainties in the epidemic trajectory after NPIs are lifted.Implications of all the available evidence Our study shows that lifting interventions must be balanced carefully and cautiously with vaccine roll-out. In the presence of a new, highly transmissible variant, vaccination alone may not be enough to control COVID-19. Careful monitoring of vaccine uptake, effectiveness, variants, and changes in contact patterns as restrictions are lifted will be critical in any exit strategy.Competing Interest StatementAC has received payment from Pfizer for teaching of mathematical modelling of infectious diseases. KAMG has received honoraria from Wellcome Genome Campus for lectures and salary support from BMGF and Gavi through Imperial College London for work outside this study. All other authors declare no competing interests.Funding StatementThis work was supported jointly by the Wellcome Trust and the Department for International Development (DFID) [221350]. We acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development [MR/R015600/1]. This work was also supported by the National Institute for Health Research Health Protection Research Unit in Modelling Methodology - a partnership between PHE, Imperial College London, and LSHTM [NIHR200908], the Abdul Latif Jameel Foundation and the EDCTP2 programme supported by the European Union. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics permission was sought for the study via Imperial College London's standard ethical review processes and was approved by the College's Research Governance and Integrity Team (ICREC reference: 21IC6945).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data files and source code are available here: https://github.com/mrc-ide/sarscov2-roadmap-england https://github.com/mrc-ide/sarscov2-roadmap-england